Influencia en la satisfacción de los pacientes tras la administración de OraVerse ® en tratamientos implantológicos
Loading...
Download
Official URL
Full text at PDC
Publication date
2019
Defense date
14/12/2018
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citation
Abstract
Antecedentes y justificación: El efecto anestésico en tejidos blandos tras la anestesia dental puede durar de 3 a 5 horas, suponiendo, en la mayoría de los casos, un tiempo superior al de trabajo. Esto puede llegar a ocasionar una disminución en la calidad de vida de los pacientes impidiendo la realización de sus actividades cotidianas. Por ello, comenzó a utilizarse el Mesilato de Fentolamina (MF), comercializado como OraVerse®, un reversor del efecto anestésico aprobado para su utilización en odontología por la FDA en 2008.Debido a que existe la teoría de que una duración prolongada del efecto anestésico ayuda al retraso de la aparición del dolor postoperatorio, se ha visto justificada la realización del presente trabajo de investigación, para evaluar si dicha duración supone realmente una disminución en el dolor y consumo de analgésicos.Objetivos: Los objetivos que se plantean en el presente estudio de investigación son los de evaluar si la utilización de OraVerse®, como reversor del efecto anestésico, tras la colocación de implantes dentales a nivel mandibular supone una mayor satisfacción por parte del paciente, sin suponer un aumento en el dolor y consumo de analgésicos posterior a la intervención, alteraciones anómalas de las constantes vitales, así como la aparición de efectos adversos...
Background and justification After dental anesthesia, the anesthetic effect in soft tissues can last from 3 to 5 hours, resulting, in most cases, in a longer duration than dental treatment. This can lead to a decrease in the patients’ quality of life, preventing them from carrying out their daily activities. Therefore, Fentolamine Mesylate (MF), marketed as OraVerse®, began to be used. It consists of a reversal of the anesthetic effect, and it has been approved for use in the dental practice by the FDA in 2008. The present research work has been justified by the assumption that a prolonged duration of the anesthetic effect may help to delay the onset of postoperative pain. Thus, it aims to evaluate whether said duration may actually represent a decrease in pain and analgesics consumption. Objectives In this research study, the following objective has been set out: to evaluate whether the use of OraVerse®, as a reversal of the anesthetic effect, after the placement of dental implants at mandibular level supposes a greater satisfaction for the patient, without increasing the pain and analgesic consumption after the intervention, anomalous alterations of the vital signs, or the appearance of adverse effects...
Background and justification After dental anesthesia, the anesthetic effect in soft tissues can last from 3 to 5 hours, resulting, in most cases, in a longer duration than dental treatment. This can lead to a decrease in the patients’ quality of life, preventing them from carrying out their daily activities. Therefore, Fentolamine Mesylate (MF), marketed as OraVerse®, began to be used. It consists of a reversal of the anesthetic effect, and it has been approved for use in the dental practice by the FDA in 2008. The present research work has been justified by the assumption that a prolonged duration of the anesthetic effect may help to delay the onset of postoperative pain. Thus, it aims to evaluate whether said duration may actually represent a decrease in pain and analgesics consumption. Objectives In this research study, the following objective has been set out: to evaluate whether the use of OraVerse®, as a reversal of the anesthetic effect, after the placement of dental implants at mandibular level supposes a greater satisfaction for the patient, without increasing the pain and analgesic consumption after the intervention, anomalous alterations of the vital signs, or the appearance of adverse effects...
Description
Tesis inédita de la Universidad Complutense de Madrid de la Facultad de Odontología. Departamento de Especialidades Clínicas Odontológicas, leída el 14-12- 2018